Loading...
OTCM
AWHL
Market cap14mUSD
Dec 05, Last price  
0.40USD
1D
-2.32%
1Q
-41.71%
Jan 2017
-57.89%
IPO
-98.88%
Name

Aspira Women's Health Inc

Chart & Performance

D1W1MN
OTCM:AWHL chart
P/E
—
P/S
1.53
EPS
—
Div Yield, %
—
Shrs. gr., 5y
19.61%
Rev. gr., 5y
15.14%
Revenues
9m
+0.31%
27,246,00018,215,00044,000124,00001,175,0001,923,0002,094,0002,566,0002,521,0002,177,0002,642,0003,121,0003,053,0004,538,0004,651,0006,812,0008,184,0009,154,0009,182,000
Net income
-13m
L-21.55%
-35,433,000-22,066,000-21,282,000-18,330,000-22,048,000-19,034,000-17,790,000-7,146,000-8,819,000-19,209,000-19,115,000-14,968,000-10,497,000-11,371,000-14,845,000-17,630,000-31,710,000-21,575,000-16,690,000-13,094,000
CFO
-12m
L-23.79%
-22,897,000-20,439,000-20,268,000-15,440,000-3,114,000-20,935,000-15,581,000-10,398,000-8,224,000-16,808,000-18,365,000-13,963,000-8,129,000-9,367,000-12,966,000-14,734,000-27,395,000-32,185,000-15,894,000-12,113,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company provides OVA1, OVERA, and OVA1plus to detect risk of ovarian malignancy in women with adnexal masses. It also offers ASPiRA GenetiX, a genetic test for the risk of gynecologic cancer. In addition, the company operates Aspira Synergy, a testing platform and cloud service for decentralized access of protein biomarker and hereditary genetic testing; and owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, its pipeline products include OVAWatch, EndoCheck, and OVAInherit. The company serves physicians, physician office laboratories, and national and regional laboratories. It has a collaborative research agreement with Baylor Genetics; an agreement with Harvard Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate the microRNA technology in combination with Aspira technologies for the development of an early detection test for ovarian cancer; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is headquartered in Austin, Texas.
URL
https://aspirawh.com/
IPO date
Sep 29, 2000
Employees
85
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT